- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Latest News
Around four months earlier, the US drugs regulator said it had found a cancer-causing impurity in some products...
Read More
Read More
In what can be a game changer for the Indian pharmaceutical industry, the Ministry of Environment and Forests (MoEF) has...
Read More
Read More
DoP officials, rather than district collectors, could be entrusted with job
Unable to...
Read More
Unable to...
Read More
Amid repeated regulatory scrutiny by different state-level authorities, online pharmacy companies are urging...
Read More
Read More
Washington: A division of the American Chemical Society (CAS), specialising in scientific information solutions, has...
Read More
Read More
CDSCO yet to finalise regulations for online drug sales or e-pharmacies. India's drugs regulator has asked all states to...
Read More
Read More
NEW DELHI, India’s proposal to cap the trade margins available to drug distributors will not significantly hurt the...
Read More
Read More
India’s Increased Dependence on Chinese APIs Causing Concern India’s dependence on China importing active...
Read More
Read More
The trade war between the US and China and the changed focus of the latter on its pharma sector, has opened up a big...
Read More
Read More
Viatris, it is. More than three months after Mylan said it would combine with Upjohn, a division of Pfizer, the two...
Read More
Read More
An analysis undertaken by BioPharma Dive has identified 31 troubled biopharma companies that are at highest risk of...
Read More
Read More
Novartis has agreed to buy New Jersey-headquartered The Medicines Company (MedCo) for US$ 9.7 billion. The buyout will...
Read More
Read More